Management

Education:
University of Copenhagen - M.Sc., Pharmacy
Smartly School of Business - MBA

Jeppe Ragnar Andersen joined Nordic Bioscience in 2007 and became Head of Clinical Development in 2010. Jeppe has been CEO of Nordic Bioscience Clinical Development A/S since January 2014.

Jeppe is actively doing research into clinical trial methodology with a special focus on implementing risk-based monitoring and cost-benefit optimization. Over the years, Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes.

He has headed the successful merging of two clinical development departments and an expansion of the department with highly motivated employees from 3 employees to 30 employees.

Education:
Copenhagen Business School - M.Sc., Business Economics

Thomas Nielsen joined Nordic Bioscience as CFO in January 2007 after being responsible for the external financial audit of the company since 2003.

Thomas is overall responsible for the administration in Nordic Bioscience which handles all financial, administrative, legal, IT and corporate matters.

Education:
University of Copenhagen - M.Sc., Pharmacy

Asger R. Bihlet joined Nordic Bioscience Clinical Development in 2013 and assumed the position as Medical Director in 2014.

Asger has wide experience from several areas of the pharmaceutical industry with previous positions including 6 years as Head of Regulatory Affairs and later as Medical Advisor within the fields of cardiovascular diseases and oncology during which he has played an integral part in the design, initiation and wrap-up of several clinical projects. Asger currently leads the Medical Affairs activities in Nordic Bioscience Clinical Development, including heading the pharmacovigilance and regulatory affairs activities.

Asger is actively researching and publishing in the fields of osteoarthritis with a particular focus on optimizing clinical trial design and outcome.

Education:
University of Copenhagen - M.Sc., Pharmacy

Sara Daugaard Popik joined Nordic Bioscience in 2011 and became Clinical Operations Director in 2016.

Sara is actively focusing on performing better, cheaper and smarter clinical operational set ups to conduct efficient clinical trials within the field of especially osteoarthritis. Over the years, Sara has been involved on an operational and management level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes.

She has headed the successful expansion of the Clinical Operations Department and NBCD Quality Management System, including implementation of Risk Based Monitoring and various computerized systems since her start in the organization almost 10 years ago.

Casper Clemmensen
Education:
University of Copenhagen - M.Sc., Pharmacy

Casper Clemmensen joined NBCD in 2016 as Clinical Trial Leader and transitioned into his current position as Business Development Director in 2019.

Casper has a longstanding background of 13 years working with clinical development across pharma and biotech headquarter positions before joining NBCD in 2016. Over the years, Casper has gained unique insight to the different actors of the pharmaceutical industry which has led to a profound understanding of current and future NBCD partners resulting in strong strategic and scientific alliances.
“The ultimate goal of our partnerships is to help patients with osteoarthritis and address one of the largest unmet medical needs.”